Abstract
Abstract In this work we describe ET-D5, a synthetic small molecule serine-threonine protein phosphatase inhibitor with proven in vivo anti-mitotic and anti-vascular properties. The potential anti-cancer properties of serine-threonine protein phosphatase inhibitors have been identified since ancient times (extract from blister beetle mylabris was used in China for cancer treatment as early as in 1264), and several, mostly natural, inhibitors were evaluated in clinical trials. Their development was, however, discontinued due to the toxic effects of these non-selective (PP2A>>PP1) serine-threonine protein phosphatase inhibitors. ET-D5 is a remarkably specific (PP1 versus PP2A) inhibitor with potent anti-mitotic and anti-vascular activities. In vitro, ET-D5 display high efficacy against a wide range of human cancer cells (GI50 values determined were in low nM range for certain cell lines). In addition, ET-D5 disrupts the in vitro preformed capillary tubes (endothelial cells HMEC-1). In vivo experiments confirmed these activities in numerous animal models of human cancer, such as cancer of lung, brain, thyroid, kidney and ovaries. ET-D5 presents interesting pharmacological properties, good toxicology profile and is also active when administered per os. Contrary to many vascular-disrupting agents (VDA) which target tubulin, ET-D5 exerts its activity by selectively inhibiting in vivo protein-phosphatase I (PP1). We confirmed this activity in classical pharmacodynamics experiments, showing PP1 inhibition in xenografted tumors after oral administration of ET-D5. Based on all these results, ET-D5 is scheduled to enter clinical trials in early 2015. Citation Format: Aurelie Juhem, Delphine Lecercle, Julie Deverchère, Arnaud Gazel, Jean-Claude Florent, Andrei Popov. ET-D5, first-in-class synthetic selective Protein Phosphatase 1 (PP1) inhibitor with anti-proliferative and anti-vascular activity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 757. doi:10.1158/1538-7445.AM2014-757
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
